相关实验视频

Updated: Jul 21, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

卡姆雷利祖马布加化疗在晚期状非小细胞肺癌中具有成本效益

Xueyan Liang¹, Xiaoyu Chen², Huijuan Li¹

¹Phase I Clinical Trial Laboratory, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China.

|July 26, 2023

概括

康美利祖马布与化疗相结合,为中国的晚期状非小细胞肺癌提供了具有成本效益的第一线治疗方法. 与单独的化疗相比,这种组合可以改善质量调整后的寿命.

科学领域:

在瘤学瘤学.
卫生经济学卫生经济学

背景情况:

晚期状非小细胞肺癌 (NSCLC) 存在重大治疗挑战.
第一线治疗选择正在不断发展,以改善患者的治疗结果.

研究的目的:

评估卡梅利祖马布加化疗与单独化疗对中国晚期状NSCLC的成本效益.
为了确定增量成本效益比率 (ICER) 和其概率.

主要方法:

利用了来自CameL-Sq临床试验的生存数据.
采用分区生存模型来评估成本效益.
进行敏感性分析以确保模型稳定性.

主要成果:

卡姆雷利祖马布加化疗导致每名患者的质量调整寿命年 (QALYs) 增加0.83.
每名患者的增量成本为21,259美元,产生了25,674美元/QALY的ICER.
无论PD-L1表达水平如何,成本效益概率都超过了90%.

结论:

卡姆雷利祖马布加化学疗法是中国高级状NSCLC的经济有效的第一线治疗方法.
处理策略在各种敏感性分析中显示出强大的成本效益.

关键词:

卡梅里兹马巴姆的摄影化学疗法化疗化疗经济效益成本效益分隔的生存模型.状非小细胞肺癌是什么?

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...